Fate Therapeutics
Stock Forecast, Prediction & Price Target
Fate Therapeutics (FATE) stock Price Target by analysts
$5
Potential upside: 338.67%
Fate Therapeutics price prediction
What is Fate Therapeutics stock analysts` prediction?
Fate Therapeutics stock forecast: Based on 1 Wall Street analysts` predicted price targets for Fate Therapeutics in the last 3 months, the avarage price target is $5, with a high forecast of $NaN. The average price target represents a 338.67% change from the last price of $1.14.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Fate Therapeutics stock Price Target by analysts
Full breakdown of analysts given Fate Therapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Etzer Darout BMO Capital | 0% 0/2 | 11 months ago | $5 338.67% upside | $3.37 | StreetInsider | Previous targets (1) |
Benjamin Burnett Stifel Nicolaus | 0% 0/1 | about 1 year ago | $5 338.67% upside | $3.27 | StreetInsider | Previous targets (0) |
Edward Tenthoff Piper Sandler | 0% 0/3 | over 1 year ago | $6 426.40% upside | $3.61 | StreetInsider | Previous targets (2) |
Debjit Chattopadhyay H.C. Wainwright | 0% 0/1 | over 1 year ago | $5 338.67% upside | $4.24 | StreetInsider | Previous targets (0) |
Bill Maughan Canaccord Genuity | 0% 0/1 | over 1 year ago | $9 689.61% upside | $3.9 | TheFly | Previous targets (0) |
Edward Tenthoff Piper Sandler | 0% 0/3 | over 1 year ago | $4 250.93% upside | $3.88 | StreetInsider | Previous targets (2) |
Etzer Darout BMO Capital | 0% 0/2 | over 1 year ago | $6 426.40% upside | $3.87 | StreetInsider | Previous targets (1) |
Unknown Goldman Sachs | N/A | over 2 years ago | $4 250.93% upside | $4.4 | Benzinga | N/A |
Unknown BMO Capital | N/A | over 2 years ago | $7 514.14% upside | $11 | Benzinga | N/A |
Unknown Piper Sandler | N/A | over 2 years ago | $12 952.81% upside | $11 | Benzinga | N/A |
Unknown Morgan Stanley | N/A | over 2 years ago | $8 601.87% upside | $4.22 | Benzinga | N/A |
Robyn Karnauskas Truist Financial | 100% 1/1 | over 2 years ago | $7 514.14% upside | $11 | TheFly | Previous targets (0) |
Andrea Tan Goldman Sachs | 100% 1/1 | almost 3 years ago | $10 777.34% upside | $15.37 | TheFly | Previous targets (0) |
Unknown Truist Financial | N/A | almost 3 years ago | $46 3935.79% upside | $15.46 | Benzinga | N/A |
Matthew Biegler Oppenheimer | 0% 0/1 | almost 4 years ago | $135 11744.18% upside | $48.98 | TheFly | Previous targets (0) |
Yigal Nochomovitz Citigroup | 0% 0/1 | almost 4 years ago | $87 7532.91% upside | $60.79 | TheFly | Previous targets (0) |
Anthony Butler Roth Capital | 100% 1/1 | almost 4 years ago | $60 5164.08% upside | $61.42 | TheFly | Previous targets (0) |
Michael Yee Jefferies | 0% 0/1 | almost 4 years ago | $145 12621.53% upside | $58.16 | Investing | Previous targets (0) |
Edward Tenthoff Piper Sandler | 0% 0/3 | about 4 years ago | $113 9814.02% upside | $67.01 | TheFly | Previous targets (2) |
Fate Therapeutics Financial Estimates
Fate Therapeutics Revenue Estimates
Fate Therapeutics EBITDA Estimates
Fate Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $55.84M N/A | $96.3M 72.43% | $63.53M -34.02% | Avg: $5.38M Low: $4.78M High: $5.98M avg. -91.52% | Avg: $4.76M Low: $2.66M High: $8.26M avg. -11.63% | Avg: $17.7M Low: $9.92M High: $30.72M avg. 271.84% | Avg: $110.3M Low: $61.86M High: $191.46M avg. 523.16% |
Net Income
% change YoY
| $-206.30M N/A | $-255.05M -23.63% | $-160.92M 36.90% | Avg: $-222.23M Low: $-242.09M High: $-86.60M avg. -38.09% | Avg: $-249.73M Low: $-221.42M High: $-140.72M avg. -12.37% | Avg: $-157.65M Low: $-308.47M High: $-67.65M avg. 36.87% | Avg: $-163.36M Low: $-319.64M High: $-70.10M avg. -3.62% |
EBITDA
% change YoY
| $-215.68M N/A | $-308.38M -42.97% | $-172.22M 44.15% | Avg: $-5.38M Low: $-5.98M High: $-4.78M avg. 96.87% | Avg: $-4.76M Low: $-8.26M High: $-2.66M avg. 11.63% | Avg: $-17.7M Low: $-30.72M High: $-9.92M avg. -271.84% | Avg: $-110.3M Low: $-191.46M High: $-61.86M avg. -523.16% |
EPS
% change YoY
| -$2.18 N/A | -$2.63 -20.64% | -$1.64 37.64% | Avg: -$1.79 Low: -$2.46 High: -$0.88 avg. -9.00% | Avg: -$1.77 Low: -$2.25 High: -$1.43 avg. 1.17% | Avg: -$1.6 Low: -$3.13 High: -$0.69 avg. 9.32% | Avg: -$1.66 Low: -$3.25 High: -$0.71 avg. -3.62% |
Operating Expenses
% change YoY
| $272.84M N/A | $404.68M 48.32% | $254.04M -37.22% | Avg: $6.94M Low: $6.17M High: $7.71M avg. -97.26% | Avg: $6.13M Low: $3.44M High: $10.64M avg. -11.63% | Avg: $22.80M Low: $12.79M High: $39.59M avg. 271.84% | Avg: $142.13M Low: $79.71M High: $246.72M avg. 523.16% |
FAQ
What is Fate Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of -4.30% in 2025-2028.
We have gathered data from 13 analysts. Their low estimate is -242.09M, average is -222.23M and high is -86.60M.
What is Fate Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 172.96% in 2025-2028.
We have gathered data from 10 analysts. Their low revenue estimate is $4.78M, average is $5.38M and high is $5.98M.
What is Fate Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of -0.53% in 2025-2028.
We have gathered data from 13 analysts. Their low earnings per share estimate is -$2.46, average is -$1.79 and high is $-0.88.
What is the best performing analyst?
In the last twelve months 1 analysts have been covering Fate Therapeutics stock. The most successful analyst is Etzer Darout.